Highest-materiality recent filing
Evolent Health shareholders elect 10 directors, approve incentive plan amendment at June 4 meeting
All 10 director nominees elected with majority support; vote tallies range from 60.0M to 65.9M 'for' votes.
Evolent Health Reports Q1 2026 Results; Revenue Up, Net Loss Narrowed
Revenue $496.2M vs $483.6M in Q1 2025; net loss improved to $26.6M from $72.3M.
Evolent Q4 2025 revenue $468.7M, net loss $429.1M; guides 2026 revenue up ~30%
Q4 2025 revenue $468.7M, full-year $1.876B. Net loss $429.1M Q4, $579.4M full year.
Evolent Health closes acquisition of Privia Management Company
Acquisition closed on December 5, 2025, per Stock Purchase Agreement dated September 23, 2025.
Evolent Health board adds Jill Smith as director; reaffirms Q4 guidance
Cheryl Scott retired from Board on Dec 1, 2025; no disagreement; 21,979 RSUs accelerated.
Evolent Q3 Adj EBITDA $39M (8.1% margin); new CFO Ramos; 2026 revenue forecast $2.5B
Q3 revenue $479.5M, net loss $26.9M; adjusted EBITDA $39.0M vs $31.8M YoY.
Evolent sells value-based primary care business Evolent Care Partners to Privia for up to $113M
ECP acquired by Privia Health Group (PRVA) for $100M cash at close plus up to $13M contingent on 2025 MSSP performance; expected close Q4 2025.
Evolent Health issues $166.75M of 4.50% convertible notes, repurchases existing notes and stock
Issued $166.75M aggregate principal of 4.50% convertible senior notes due 2031 at 100% par.
Priced $145M (upsized from $140M) of 4.50% convertible senior notes due 2031; initial purchasers have 30-day option for additional $21.75M.
Evolent Health Announces $140M Convertible Note Offering and Discloses DOJ Investigation
Evolent Health intends to offer $140.0M aggregate principal amount of convertible senior notes due 2031, with an option for an additional $20.0M.
Evolent Q2 revenue falls 31% to $444M, net loss deepens to $51M; raises FY profitability outlook
Revenue $444.3M, down 31% YoY from $647.1M; net loss $51.1M vs $6.4M loss in prior year.
Evolent reaffirms FY2025 Adj. EBITDA guidance $135-165M; secures Ares non-dilutive financing
Reaffirmed FY2025 Adj. EBITDA guidance $135-165M and Q2 2025 guidance $33-40M.
Evolent Health reports 2025 annual meeting results; all directors elected, say-on-pay passes
All ten director nominees elected on June 5, 2025, including Toyin Ajayi, Seth Blackley, Kim Keck, Brendan Springstubb.
Evolent Health reaffirms FY2025 revenue guidance of $2.06B-$2.11B at William Blair conference
Reaffirms FY2025 revenue guidance of $2.06B-$2.11B and Adjusted EBITDA of $135M-$165M.
Evolent Health Q1 revenue down 24% to $483.6M; net loss widens to $72.3M
Revenue $483.6M vs $639.7M YoY; net loss $72.3M vs $25.2M YoY.
Director Holder not re-standing; former CVS Health CFO Shawn Guertin nominated to Evolent board
Diane Holder will not stand for re-election at June 5, 2025 annual meeting; departure not due to any disagreement.
Evolent Q4 2024 revenue $646.5M (+16.3% YoY); net loss $30.6M, adjusted EBITDA $22.6M
Revenue $2,554.7M full year 2024, +30.1% YoY; net loss $93.5M, net loss margin (3.7)%.
Evolent Health enters cooperation with Engaged Capital, appoints Springstubb to board
Appointed Brendan Springstubb (Engaged Capital affiliate) to Board; he joins Strategy Committee.
Evolent Health borrows $200M in delayed draw term loans for general corporate purposes
On Jan 24, 2025, Borrower gave notice to draw $125M (2024-A) and $75M (2024-B) delayed draw term loans, funding Jan 31.
Evolent Health to present at JPM Healthcare Conference; no material new data in filing
Presentation scheduled for Jan 14, 2025 at 4:30 PM PT at the 43rd Annual J.P. Morgan Healthcare Conference.
Evolent Health amends credit agreement adding $250M in new debt facilities
Increased existing ABL revolver by $50M (with $25M funded); new delayed draw term loans of $125M and $75M.
Evolent Q3 revenue rises 21.6% to $621M, net loss $31.2M; EBITDA miss due to $42M medical cost spike
Revenue $621.4M, up 21.6% YoY; net loss $(31.2)M vs $(33.2)M prior year.
Evolent Q2 revenue $647M (+38% YoY); net loss narrows to $6.4M; Adj. EBITDA $52M; narrows FY outlook
Revenue $647.1M, up 37.9% YoY from $469.1M; net loss $(6.4)M vs $(41.4)M loss in Q2 2023.
Evolent Health annual meeting: all 10 directors elected, auditor ratified, say-on-pay approved
All 10 director nominees elected; Diane Holder received 8.6M against votes (8.4% of votes cast).
Evolent Health acquires Machinify assets for $25M cash plus up to $7M earn-out
Cash consideration of $25M plus up to $7M earn-out; perpetual royalty-free license of Machinify Auth AI platform.
Evolent Health Q1 revenue $639.7M (+49.6% YoY); raises FY2024 revenue guide
Revenue $639.7M, net loss $(25.2)M; Adjusted EBITDA $54.1M (8.5% margin).
Diane Holder notified the Board of Directors (the “Board”) of Evolent Health, Inc. (the “Company”) that she will not stand for re-election to the Board at the Company’s annual meeting of stockholders scheduled to be held on June 5, 2025 (the “2025 Annual Meeting”).
On February 3, 2025, M. Bridget Duffy, MD resigned from the Board.
On February 4, 2025, the Board (1) appointed Mr. Springstubb as a director
Max materiality 0.90 · Median 0.68 · Most common event earnings